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OBJECTIVES: The use of multimodal analgesic management has been implemented
forminimizing adverse events and to improve thepatient recovery processwhichwill
have a significant impact on clinical and economic outcomes. The aim of this study
was to develop an economic assessment of parecoxib, ketorolac andmorphine for the
treatment of postoperative pain (POP) for patients after total abdominal hysterectomy
at the Social Security Mexican Institute (IMSS) from an institutional perspective.
METHODS: A Bayesian decision-tree model was developed to simulate costs and
health outcomes over a 6-day time period in patients treated with multimodal anal-
gesic. Comparators assessed were: morphine (61.5 mg/day) plus parecoxib (40 mg/
day); morphine (61.5 mg/day) plus ketorolac (90 mg/day) and morphine (61.5mg/day)
alone. The effectiveness measure was: percentage of successful response without
adverse events(AE) meeting the highest possible score for patient’s global evaluation
survey (excellent). This survey has been previously validated in Mexico. Costs and
resource usewere collected fromhospital records related to patients undergoing total
abdominal hysterectomy at IMSS in 2008 (n98). Transition probabilities were col-
lected from international published literature andmodel was calibrated according to
international pharmacoeconomics guidelines. One way and probabilistic sensitivity
analyses were performed by Monte Carlo Simulation second-order approach.
RESULTS: Percentageof successful responsewithoutAE resulted forparecoxib in35%,
followed by ketorolac with 24% and morphine with 21%. Estimated cost per patient
treated were lower for ketorolac (US$ 5,309.20) followed by morphine (US$5,343.96)
andparecoxib (US$5,375.78). Nomeaningful statistical differenceswere found in costs
among competing alternatives (p0.05). ICER for additional successful response was
US$ 601.29 for parecoxib against keterolac. Acceptability curves showed that pare-
coxib is the most cost-effective therapy with 90% at a willingness to pay of US$4,500.
CONCLUSIONS: Parecoxib represents a cost-effective analgesic alternative for POP
management in patients who underwent abdominal hysterectomy at the IMSS.
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OBJECTIVES: Treatment of vasomotor symptoms (VMS) inwomenwith breast can-
cer (BC) represents a challenge while the use of hormone replacement therapy
(HRT) in these patients could be not suitable. The purpose of this study was to
estimate the cost-effectiveness of pharmacological treatments for VMS in BC pa-
tients from an institutional perspective. METHODS: A Markov model was per-
formed to estimate health and economic consequences in a time horizon of five
years (quarterly cycles). Effectiveness measures were: reduction of hot flashes
events and QALY’s gained. Comparators assessed were: conjugated estrogens (CE;
0.625mg/day, only used in hysterectomized women), CEmedroxyprogesterone
(2.5mg0.625m/day, only used in non-hysterectomized women), tibolone (2.5mg/
day), no treatment (no candidates to HRT) and desvenlafaxine (100mg/day) as ref-
erence treatment in all indications. Transition probabilities were collected from
published data. Resource use was obtained from clinical files (n140) from Insti-
tutoMexicano del Seguro Social (IMSS) and includes pharmacological treatment for
VMS, screening for HRT eligibility and side effect management. Official institu-
tional costs were used. Probabilistic sensitivity analyses were performed and ac-
ceptability curves were constructed. RESULTS: Compared to no treatment, des-
venlafaxine resulted more costly (US$1,072.68), but avoided 2,753.8 more hot
flashes (ICERUS$0.39/additional hot flash avoided) and gained 0.75 QALY=s
(ICERUS$1,430.24/QALY gained) in no candidates to HRT. In hysterectomized
women, desvenlafaxine cost was US$2,723.76 and dominates CE (incremental:
US$354.64; 441.45 hot flashes, -0.16 QALY=s) and tibolone (incremental:
US$564.94; 811.74 hot flashes; -0.21 QALY=s). In non-hysterectomized women,
desvenlafaxine cost was US$2,866.51 and dominated tibolone (US$3,522.33;
2,297.82 hot flashes and 0.59 QALY=s) and CEmedroxyprogesterone (incremental:
US$855.34;1,764.87 hot flashes; -0.38 QALY=s). Acceptability curves showed that
regardless willingness to pay, desvenlafaxine is likely to be cost-effective against
competing alternatives. CONCLUSIONS: At IMSS, the management of VMS with
desvenlafaxine is a cost-saving alternative for both hystererctomized and non-
hysterectomized BC patients, as well as cost-effective for no candidates to HRT.
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OBJECTIVES: To evaluate the cost-effectiveness of an intervention, Advancing Bet-
ter Living for Elders (ABLE), which was shown to reduce mortality in community-
dwelling elders in a randomized trial. METHODS: 319 community-living older
adults randomized to ABLE or no-treatment control group, were included in the
economic analysis. ABLE involved occupational and physical therapy home and
telephone sessions and home modifications (e.g., grab bars) to address functional
difficulties over 12months. Using ahome-care agency perspective, the incremental
cost-effectiveness ratio (ICER) was expressed as the additional cost to bring about
one additional year of life. To account for potential variations in costs of imple-
menting ABLE in different settings, two models were developed: cost of imple-
menting ABLE and cost 10%. Probabilistic sensitivity analysis was conducted to
account for variation onmodel parameters. Confidence intervals for the ICERswere
calculated using the Fieller theorem method. RESULTS: Total cost of ABLE per
participant after discounting was $908. In the secondary cost-effectiveness analy-
ses total cost after discounting equaled (10%) $999. By 2 years, there were 30
deaths (9 in ABLE and 21 in Control). Life year saved for ABLE was .944 compared to
.868 for the intervention. Under assumptions ofmodels 1 and 2 the additional costs
for 1 additional year of life were $12,985 (95% CI: $4,637-$87,905); and $14,271 (95%
CI: $5,068-$107,539); respectively. CONCLUSIONS: This economic evaluation sug-
gests that investment in this program may be worth while depending on ones
willingness to pay. However, confidence intervals varied widely due to small effect
in reducing mortality.
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OBJECTIVES: We have examined the impact of long term disability costs arising
from increased use of IVF treatments in relation to multiple births reductions in
Canada. METHODS: Using the Canadian Fertility Cost Model we estimated the
potential cost savings of reducing the number ofmultiple pregnancies in Canada. A
series of probabilistic analyses were performed to account for the effect of uncer-
tainty in long-term outcomes and disability costs on the cost effectiveness of re-
ducing multiple births. Values for disability rates were sampled from a beta distri-
bution and costs were sampled from a log-normal distribution. Simulation results
were generated by simultaneously varying long-termdisability rates and costs. The
outcomes included age-specific net total costs, lifetime disability costs, and incre-
mental costs per live birth. RESULTS: Assuming reductions in multiple birth rates
equal to those reached by selected European countries, we estimated that, over the
next five years in Canada, the multiple birth rates could be reduced from 28.8% to
13.4%. Using Monte-Carlo simulations, the potential cost savings range from $150
million to $558million, and the reduction in over-all incremental cost per live birth
range from $8,560 to $31,897. The proportions of children with lifetime disabilities
range from 6.0% to 24.0% for current practice, and 4.3% to 17.3% assuming reduc-
tions inmultiple births. Forwomen under 35, aged 35-39, and over 40, reductions in
over-all incremental cost range from ($9,555 - $35,616), ($7,814 - $29,977) and
($6,031 - $22,543), respectively. The bulk of cost reductions (ranging from 50% to
87%) would be attributable to reductions in disability costs. CONCLUSIONS: Our
analysis shows that a reduction in multiple births would result in potential cost
savings. The amount of variation in the long term outcomes and disability costs
make the projections, nevertheless, highly unstable.
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OBJECTIVES:More than 8.8 million children under 5 die globally before they reach
the age of five. In Kenya, under fivemortality rate was 74 per 1000 children in 2008.
To improve care for seriously ill children, a multifaceted approach employing
guidelines, training, supervision, feedback and facilitationwas developed, for brev-
ity called the Emergency Triage and Treatment Plus (ETAT) strategy.We assessed
the costs and efficiency of delivery of the ETAT strategy in district hospitals in
Kenya. METHODS: A cost-effectiveness analysis from the provider’s perspective
was conducted alongside a cluster randomized study that compared the delivery of
ETAT in four district hospitals in Kenya to four control district hospitals receiving
a partial version of the intervention between 2005 and 2009. Effectiveness of the
interventionwasmeasured using 14 processmeasures that capture improvements
in quality of care and span the assessment, diagnosis and treatment on admission
in children under five. Economic costs were estimated through interviews with
implementers of the intervention, accounting and clinical record reviews. An an-
nual discount rate of 3% was used and one way sensitivity analyses were used to
assess uncertainty. Incremental cost-effectiveness ratios (ICERs) were defined as
the cost per percentage improvement in quality of care. RESULTS: The cost per
child admission was US$ 54.74 in intervention hospitals compared to US$ 31.06 in
control hospitals, while quality of care as measured by the 14 process measures
was 23.05% higher in intervention hospitals than in the control hospitals. These
results suggest an additional cost of US$ 0.85 to achieve a percentage improvement
in quality of care. CONCLUSIONS: The delivery of ETAT as a multifaceted inter-
vention yields significant improvements in quality of care but at a higher cost.
Knowing what value decision makers place on quality improvement would be
useful in making decisions about their adoption explicit.
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